Roche up in arms as NICE advises NHS not to use Perjeta

07 Aug 2013

• By Gemma Collier

NICE, the health technology assessment institute for England and Wales, is gearing up to advise the NHS that Roche's breast cancer drug Perjeta (pertuzumab) should not be routinely used as it is not value for money. The Swiss pharma company has responded with strong criticism of the Department of Health (DH), which has delayed a review of the company's proposed patient access scheme, accusing it of letting patients down and pointing to flaws in the UK's "creaking system."

NICE's advice has not yet been finalized. The institute delivered its opinion in draft guidance on 6 August and is...

ASCO: Pushing The Frontiers Of ADCs

19 Jun 2025

• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

17 Jun 2025

• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.

Enliven Raises $230m To Fund Scemblix Leukemia Challenger

17 Jun 2025

• By Andrew McConaghie

The company believes its drug could eventually displace Novartis’s Scemblix in first-line chronic myeloid leukemia treatment, but for now is preparing for a second-/third-line pivotal study.

BMS’s Breyanzi Stands To Further Expand Broad Lymphoma Coverage

16 Jun 2025

• By Alaric DeArment

The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.